On September 23, 2024, ROSENWALD LINDSAY A MD, President, CEO & Chairman, and 10% Owner of Fortress Biotech Inc (FBIO, Financial), purchased 763,359 shares of the company. Following this transaction, the insider now owns a total of 3,657,264 shares of Fortress Biotech Inc. The transaction details are filed with the SEC and can be found in the SEC Filing.
Fortress Biotech Inc is a biopharmaceutical company involved in the development of novel pharmaceutical and biotechnology products.
Over the past year, ROSENWALD LINDSAY A MD has been actively buying shares, with a total of 2,510,874 shares purchased and no shares sold. The insider transaction history for Fortress Biotech Inc shows a trend with 7 insider buys and only 1 insider sell over the past year.
Shares of Fortress Biotech Inc were trading at $1.84 on the day of the transaction, giving the company a market cap of $32.167 million. The stock's valuation metrics, such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are calculated based on historical trading multiples, adjustments for past performance, and future business projections.
According to the GF Value, the intrinsic value of the stock is estimated at $41.59, which suggests that the stock is currently undervalued, with a price-to-GF-Value ratio of 0.04. This categorizes the stock as a Possible Value Trap, indicating that investors should think twice before investing.
This recent purchase by ROSENWALD LINDSAY A MD could signal a strong belief in the future prospects of Fortress Biotech Inc, despite the current valuation indicating caution.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
